Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa
TLDR
Recombinant LysSS demonstrated that LysSS can be a novel and promising antimicrobial agent against MRSA and MDR Gram-negative bacteria including A. baumannii and P. aeruginosa.Abstract:
Objectives Multidrug-resistant (MDR) bacteria are a major public-health concern. Bacteriophage endolysins (lysins) can be used as novel antimicrobial agents against bacterial infections. In this study, a novel endolysin (LysSS) containing a lysozyme-like domain was evaluated for its antibacterial activity against various species of bacteria. Methods The LysSS-encoding gene was analyzed and cloned and the LysSS recombinant protein was expressed and purified. Purified LysSS was used to determine its antimicrobial activity against various bacterial species in vitro and to measure its protection rate against Acinetobacter baumannii systemic infection in an in vivo murine model. Results Recombinant LysSS showed activity against MDR A. baumannii, MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Pseudomonas aeruginosa and Salmonella sp. without pre-treatment with an outer membrane permeabiliser. Moreover, LysSS inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA). The minimum inhibitory concentration (MIC) of LysSS against 16 MDR A. baumannii strains ranged from 0.063–0.25 mg/mL. LysSS had no cytotoxic effect on A549 human lung cells below 250 μg/mL. In an animal model, mice infected with A. baumannii were protected (40% survival rate with 125 μg LysSS) by intraperitoneal injection of LysSS. Conclusion The current results demonstrate that LysSS may be a novel and promising antimicrobial agent against MRSA and MDR Gram-negative bacteria, including A. baumannii and P. aeruginosa.read more
Citations
More filters
Journal ArticleDOI
Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
Prasanth Manohar,Belinda Loh,Sudarsanan Athira,Ramesh Nachimuthu,Xiaoting Hua,Susan C. Welburn,Sebastian Leptihn,Sebastian Leptihn +7 more
TL;DR: In this paper, the potential of phage therapy and phage-derived therapeutic proteins and strategies in treating secondary bacterial infections, including their application in combination with chemical antibiotics, were explored.
Journal ArticleDOI
Phage-Encoded Endolysins.
Fatma Abdelrahman,Maheswaran Easwaran,Oluwasegun I. Daramola,Samar Ragab,Stephanie A. Lynch,Tolulope J. Oduselu,Fazal Mehmood Khan,Akomolafe Ayobami,Fazal Adnan,Eduard Torrents,Swapnil Sanmukh,Ayman El-Shibiny +11 more
TL;DR: In this paper, the synergy between endolysins and antibiotics is discussed, as well as the formulation of endolysin formulations for clinical trials involving endolySins, and the authors provide new insights into the synergy and synergy between the two drugs.
Journal ArticleDOI
Bacteriophage-derived endolysins to target gram-negative bacteria
TL;DR: While lysins demonstrates clear potential in managing bacterial infections caused by the drug-resistant G-ve bacteria, there are still challenges hindering their translation into clinical settings, including safety issues with OMP use, low efficiency against stationary phase bacteria and problems in stability.
Journal ArticleDOI
Advanced engineering of third-generation lysins and formulation strategies for clinical applications
Vincent De Maesschalck,Vincent De Maesschalck,Diana Gutiérrez,Jan Paeshuyse,Rob Lavigne,Yves Briers +5 more
TL;DR: This review focuses on third-generation and advanced formulation strategies that are developed to treat infections, ranging from topical to systemic applications, and may fully unlock the potential of lysin therapy and will propel it as a true antibiotic alternative or supplement.
Journal ArticleDOI
Antimicrobial Peptide Cec4 Eradicates the Bacteria of Clinical Carbapenem-Resistant Acinetobacter baumannii Biofilm.
TL;DR: Cec4 may represent a new choice for the prevention and treatment of clinical infections, and may also provide a theoretical basis for the development of antimicrobial peptide drugs.
References
More filters
Journal ArticleDOI
Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?
TL;DR: This review discusses advantages and limitations of both agents concerning their specificity, mode of action, structural issues, resistance development, pharmacokinetics, product preparation, and interactions with the immune system and describes the current regulations for phage-based product application.
Journal ArticleDOI
Bacteriophage biocontrol of foodborne pathogens
Mustafa Kazi,Uday S. Annapure +1 more
TL;DR: This article reviews in detail the application of phages for the control of foodborne pathogens in a process known as “biocontrol”.
Journal ArticleDOI
A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa.
Mingquan Guo,Chunyan Feng,Jie Ren,Xuran Zhuang,Yan Zhang,Yongzhang Zhu,Ke Dong,Ping He,Xiaokui Guo,Jinhong Qin +9 more
TL;DR: Results show that LysPA26 is a new and promising antimicrobial agent for the combat of Gram-negative pathogens.
Journal ArticleDOI
Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii.
Mya Thandar,Rolf Lood,Benjamin Y. Winer,Douglas R. Deutsch,Chad W. Euler,Vincent A. Fischetti +5 more
TL;DR: The prospect of using peptide derivatives from bacteriophage lysins to treat topical infections and remove biofilms caused by Gram-negative pathogens is demonstrated.
Journal ArticleDOI
Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1
Soo Youn Jun,Gi Mo Jung,Seong Jun Yoon,Myoung Don Oh,Yun-Jaie Choi,Woo-Jong Lee,Joon-Chan Kong,Jae Goo Seol,Sang Hyeon Kang +8 more
TL;DR: The results presented in this article strongly support SAL200 as a highly potent bactericidal agent against MRSA with an adequate pharmaceutical formulation.